All In Biotech

Drug Trial Radar · NCT06745557

Phase III Study With an Autologous Dermo-epidermal Skin Substitute for the Treatment of Burns in Adults and Adolescents

A Multicentre, Intra-patient Randomised Controlled Phase III Study to Confirm the Efficacy and Safety of denovoSkin™, a Bilayer Engineered Collagen-based Skin Graft Composed of Autologous Fibroblasts and Keratinocytes, for the Treatment of Patients With Deep Partial and Full-thickness Burns

Last checked: Nov 19, 2026Latest source record: Aug 10, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

RecruitingPivotal-lookingPhase 3. This is a heuristic, not a regulatory label.

Status

Recruiting

Enrollment

70

Planned (sponsor's estimate)

Start

Dec 13, 2024

Primary completion

Jun 30, 2027

Study completion Jun 30, 2029

Sponsor

Lead sponsor
CUTISS AGIndustry
Sponsor type
Industry
Collaborators
RCTs
First posted
Dec 20, 2024

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Single group
Masking
None
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 12 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This multicentre phase III clinical trial will target adults and adolescents of 12 years and older with severe burns to confirm the efficacy and functionality of denovoSkin™ in achieving wound closure and reducing scarring in patients with deep partial and full-thickness burns as compared to split-thickness skin.

Conditions

  • Burns

Interventions

  • denovoSkin(TM)Biological

    Transplantation of autologous dermo-epidermal skin substitute denovoSkin(TM) to the experimental area

  • STSGOther

    Transplantation of autologous split-thickness skin to the control area

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. A composite endpoint whereby success is defined by meeting both of the following criteria: - Wound closure - Scar quality (POSAS v2.0)Time frame: 6 months post grafting

Locations

19 sites in 9 countries. Site status is shown where the registry gives one.

  • CHU de Liège Département de pharmacie hospitalière - Secteur Essais cliniques

    Liège, Belgium · Recruiting

  • Hopital Edouard Herriot Centre des Brûlés de Lyon

    Lyon, France · Recruiting

  • Pharmacie Hôpital Conception

    Marseille, France · Recruiting

  • Centre Hospitalier Universitaire de Montpellier

    Montpellier, France · Recruiting

  • BG Klinikum Unfallkrankenhaus Berlin

    Berlin, Germany · Recruiting

  • BG Klinikum Bergmannstrost Halle

    Halle, Germany · Recruiting

  • Medizinische Hochschule Hannover

    Hanover, Germany · Not yet recruiting

  • BG-Unfallklinik Murnau

    Murnau am Staffelsee, Germany · Recruiting

  • Santobono-Pausilipon

    Naples, Italy · Recruiting

  • Azienda Ospedaliera di Rilievo Nazionale A. Cardarelli

    Naples, Italy · Recruiting

  • AOU Padova

    Padova, Italy · Not yet recruiting

  • Rode Kruis Ziekenhuis

    Beverwijk, Netherlands · Recruiting

  • Maasstad Hospital Dep. Burn Wound Centre

    Rotterdam, Netherlands · Recruiting

  • Samodzielny Zakład Opieki Zdrowotnej z siedzibą w Łęcznej

    Łęczna, Poland · Recruiting

  • Unidade de Queimados do CHUC

    Coimbra, Portugal · Recruiting

  • Hospital Universitario Vall d'Hebron

    Barcelona, Spain · Recruiting

  • Hospital Universitario La Paz Edificio Traumatología

    Madrid, Spain · Recruiting

  • Hospital Universitatrio y Politécnico La Fe

    Valencia, Spain · Recruiting

  • Universtitätsspital Zürich

    Zurich, Switzerland · Recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.